Standout Papers

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development 2013 2026 2017 2021 436
  1. Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development (2013)
    Qingjie Ding, Zhuming Zhang et al. Journal of Medicinal Chemistry

Immediate Impact

3 by Nobel laureates 2 from Science/Nature 67 standout
Sub-graph 1 of 22

Citing Papers

MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
2024 Standout
Polymeric Nanoparticles for Drug Delivery
2024 Standout
67 intermediate papers

Works of Kelli Glenn being referenced

Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach
2014
Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties
2009
and 7 more

Author Peers

Author Last Decade Papers Cites
Kelli Glenn 679 880 129 179 20 1.3k
Uma Yasothan 427 599 47 231 30 1.4k
Sudhir B. Kondapaka 492 902 54 125 20 1.5k
Martin Schröder 281 655 63 135 44 1.2k
Sheila Miknyoczki 390 539 61 76 19 1.0k
C A O'Brian 390 944 21 60 28 1.4k
Smitha Pillai 464 1133 215 70 34 1.7k
Sagar Agarwal 908 637 46 41 28 1.7k
J A Double 520 811 39 191 28 1.7k
Bedrich L. Eckhardt 612 730 42 165 26 1.5k
Grégoire Prévost 639 1005 21 179 56 1.6k

All Works

Loading papers...

Rankless by CCL
2026